Novadaq Technologies Inc.TSX: NDQ

Novadaq to hold second quarter 2006 conference call and webcast

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, Aug. 1 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, will host a
conference call and live webcast on Tuesday, August 8, 2006 at 4:30 p.m. E.T.
to discuss the financial results for the second quarter ended June 30, 2006.
To access the conference call by telephone, dial 416-644-3417 or
1-800-814-4861. Please connect approximately ten minutes prior to the
beginning of the call to ensure participation. The conference call will be
archived for replay until August 15, 2006 at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21197987 followed by the number sign.
A live audio webcast of the conference call will be available at
www.novadaq.com. Please connect at least ten minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above website for
90 days.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX(R) System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is designed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases